Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Septerna logo — Bringing a new era of GPCR medicines to patients with its Na...

Septerna

Bringing a new era of GPCR medicines to patients with its Native Complex Platform™.

Founded 2022 United States South San Francisco, United States 137 employees IPO Total: $552.60M Biotechnology, Pharmaceutical

General Information

Company Name Septerna
Founded Year 2022
Location United States South San Francisco, United States +1
Employees 137
Industries Biotechnology, Pharmaceutical
Funding Stage IPO
Social

Get notified when Septerna moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Septerna, having recently completed its IPO, is demonstrating active post-listing execution by recruiting for key positions and preparing to present significant scientific data on its lead candidate, SEP-479, at ENDO2026. This participation signals continued progress in its therapeutic pipeline and a strategic focus on showcasing clinical or preclinical advancements to the scientific community and potential stakeholders. The combination of talent acquisition and public data presentation underscores the company's commitment to advancing its GPCR-targeted medicines.

Signal Types
Hiring Product Development Visibility Increase
Strategic Labels
Pipeline Advancement Scientific Validation Talent Acquisition
Next Move: Clinical Update
·
Impact: 8/10
·
Ideal For: Biotech Investors — Post-IPO, Growth Equity — Pharmaceutical Development

About Septerna

Septerna, founded in 2022, is a biotechnology and pharmaceutical company headquartered in the United States. With the slogan, "Bringing a new era of GPCR medicines to patients with its Native Complex Platform™," the company is pioneering innovations in the GPCR landscape.

Septerna aims to transform the potential of GPCR medicines into reality through cutting-edge biochemical, structural, and computational drug discovery methods. The company's hallmark, the Native Complex Platform™, facilitates precise modulation of GPCR biology, thereby expanding small molecule discovery in the field.

The startup has recently attracted significant interest, securing a $302.60M IPO investment as of 01 October 2024. Septerna continues its quest toward revolutionizing patient care by actively seeking talented individuals to join its mission-driven team.

Taxonomy: GPCR medicines, Native Complex Platform, small-molecule drugs, drug discovery, biochemical advances, structural drug development, computational drug discovery, pharmacology, high-impact medicines, G protein-coupled receptors, medicinal chemistry, innovation in healthcare, patient-centric solutions, bioscience research

Services & Products

Discovery of GPCR-targeted drug candidates
Development of oral small molecule therapies
Optimization of GPCR drug targets

Target Customers

Patients with unmet medical needs Healthcare providers Medical researchers Pharmaceutical investors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
IPO •••••• - 01 Oct 2024
Series B •••••• 15
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
01 Jul 2023
Spinout •••••• 7
Investor Investor Investor Investor Investor Investor Investor
01 Jan 2022

Septerna Alternatives & Competitors

View All Alternatives
Septerna vs
CLOVERNA
CLOVERNA Japan

RNA targeted drug discovery

1 employees
Biopharma, Biotechnology
Compare Septerna vs CLOVERNA
Septerna vs
Design Pharmaceuticals Inc.
Design Pharmaceuticals Inc. United States

Boundless GPCR drug discovery

Seed
3 employees
Biotechnology, Health Care
Compare Septerna vs Design Pharmaceuticals Inc.
Septerna vs
Cytonus Therapeutics
Cytonus Therapeutics United States

Launching a Therapeutic Revolution to Transform Your Health©️

Series A
11 employees
Compare Septerna vs Cytonus Therapeutics
View all alternatives

FAQ About Septerna

Bringing a new era of GPCR medicines to patients with its Native Complex Platform™.
Septerna was founded in 2022.
Septerna is headquartered in South San Francisco, United States.
Septerna operates in the following industries: Biotechnology, Pharmaceutical.
Septerna has approximately 137 employees.
Septerna has completed 3 funding rounds, raising a total of $552.60M. The latest funding stage is IPO.
Septerna offers: Discovery of GPCR-targeted drug candidates, Development of oral small molecule therapies, Optimization of GPCR drug targets.
Top alternatives and competitors to Septerna include CLOVERNA, Design Pharmaceuticals Inc., Cytonus Therapeutics, Related Sciences, Nxera Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Septerna and CLOVERNA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Septerna and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy